

2018 Topical Testosterone Prior Authorization Request

Page 1 of 2

(You must complete both pages.)

Coverage Criteria for Androderm patch, Axiron solution, and testosterone solution (generic Axiron):

Medication is covered when being prescribed for replacement therapy in male members (or a member that self-identifies as male) for conditions associated with a deficiency or absence of endogenous testosterone such as primary or hypogonadotropic hypogonadism **AND**

- For therapy initiation: the member has had at least TWO confirmed low testosterone levels according to current practice guidelines or the standard male lab reference values
- For continuation of therapy: the member has had ONE confirmed low testosterone level BEFORE STARTING testosterone therapy
 according to current practice guidelines or the standard male lab reference values
- Authorization period: Through end of plan contract year.

Coverage Criteria for Androgel gel, Androgel Pump gel, Fortesta gel, Natesto gel, Striant buccal system, Testim gel, testosterone gel, and Vogelxo gel:

Medication is covered when being prescribed for replacement therapy in male members for conditions associated with a deficiency or absence of endogenous testosterone such as primary or hypogonadotropic hypogonadism when not being used solely for muscle building purposes and when being used in the absence of carcinoma of the breast or suspected carcinoma of the prostate AND

- For therapy initiation:
 - Member has tried and failed, or has a contraindication or intolerance to Axiron (testosterone solution) AND Androderm (testosterone patch) AND
 - 2. Member has had either ONE low total testosterone level **OR** ONE low free testosterone level (below the normal range for the laboratory)
- For continuation of therapy: covered for members that are already stabilized on the medication who have tried and failed, or have a contraindication or intolerance to Axiron (testosterone solution) AND Androderm (testosterone patch) (labs not required)
- Medication is not covered for members with testosterone levels within normal limits prior to initiating therapy.
- Authorization period: Through end of plan contract year.

Fax completed form to: 1-800-639-9158

For urgent requests, please call: 1-800-551-2694

| Patient information | | Prescrib | er informa | tion | | | |
|--|-----------------------|------------------------|--------------------------------------|--------|---------------|----------------------------|--|
| Patient name | | Today's o | late Physician sp | | Physician spe | cialty | |
| Patient insurance ID number | | | name | | | NPI/DEA number | |
| Patient address, city, state, ZIP | | | Physician address, city, state, ZIP | | | | |
| Patient home telephone number | | | M.D. office telephone number | | | | |
| Gender ☐ Male ☐ Female | Patient date of birth | M.D. office fax number | | | | | |
| Diagnosis and medical information | on | | | | | | |
| Medication requested ☐ Androderm transdermal patch (preferred) ☐ Axiron topical solution (preferred) ☐ testosterone 30mg/act solution ☐ (generic Axiron) (preferred) ☐ Androgel gel ☐ Fortesta gel ☐ Other: | | | Strength and route of administration | | e of | Frequency | |
| New prescription OR date therapy i | nitiated | | Quantity | Day si | upply | Expected length of therapy | |
| Diagnosis (Please include all office notes supporting diagnosis.) Male hypogonadism Other diagnosis/(ICD 10): | | | | | | | |

(continued on page 2)

Fax Confidentiality Notice: The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). The message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to criminal or civil penalties. If you received this transmission in error, please notify us immediately by telephone at 1-800-551-2694.



Page 2 of 2

| Please check all boxes that apply: | | | | | | |
|--|---|--------------------------------------|--|--|--|--|
| 1. All covered Part D drugs on any tier of the plan's formulary would not be as effective for the enrollee as the requested formulary drug and/or would likely have adverse effects for the enrollee. | | | | | | |
| 2. Patient is stable on current drug(s) and/or current quantity, medication change would likely result in high risk of significant adverse clinical outcomes. | | | | | | |
| 3. Yes No | For all requests EXCEPT Androderm, Axiron, and testosterone solution (generic Axiron), has the member tried and failed, or does the member have a contraindication or intolerance to, Axiron (testosterone solution) AND Androderm (testosterone patch)? | | | | | |
| 4. Yes No | Is this a request for INITIATION of therapy for a male patient with hypogonadism? If yes, please provide TWO testosterone levels for Androderm, Axiron and testosterone solution (generic Axiron) requests and ONE testosterone level for all other topical testosterone product requests. | | | | | |
| | Testosterone Level: circle one (Total / Free) level laboratory range Testosterone Level: circle one (Total / Free) level laboratory range | - | | | | |
| 5. Yes No | Yes No Is this a request for CONTINUATION of therapy for a male patient with hypogonadism? If yes, please provide ONE testosterone level prior to starting therapy for Androderm, Axiron and testosterone solution (generic Axiron) requests. No levels are needed for the other topical testosterone product requests. | | | | | |
| | Testosterone Level: circle one (Total / Free) level laboratory range | (low /high/ normal) | | | | |
| 6. Please review the | exclusion criteria below for topical testosterone and check all that apply: | | | | | |
| ☐ Patient has testosterone levels within the normal range BEFORE initiating therapy (normal range for the lab doing the testing) | | | | | | |
| ☐ Patient is fema | е | | | | | |
| ☐ Patient is a male with carcinoma of the breast or suspected carcinoma of the prostate | | | | | | |
| ☐ Medication is being used for muscle building purposes | | | | | | |
| | | | | | | |
| 7. Other supporting information *NOTE: All exception requests require prescriber supporting statements. Requests that are subject to prior authorization (or any other utilization management requirement), may require supporting information. Please attach supporting information, as necessary, for your request. | | | | | | |
| - | | _ | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | _ | | | | |
| Lattest that the med | cation requested is medically necessary for this nation. I further attest that the info | mation provided is accurate and true | | | | |
| I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that documentation supporting this information is available for review if requested by the health plan sponsor, or, if applicable, a state or | | | | | | |
| federal regulatory agency. I understand that any person who knowingly makes or causes to be made a false record or statement that is | | | | | | |
| material to a claim ultimately paid by the United States government or any state government may be subject to civil penalties and treble | | | | | | |
| damages under both the federal and state False Claims Acts. See, e.g., 31 U.S.C. §§ 3729-3733. By signing this form, I represent that I have obtained patient consent as required under applicable state and federal law, including but not limited to the Health Information Portability and | | | | | | |
| Accountability Act (HIPAA) and state re-disclosure laws related to HIV/AIDS. | | | | | | |
| Prescriber signatu | Date | | | | | |
| | | | | | | |
| | | | | | | |

Fax Confidentiality Notice: The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). The message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to criminal or civil penalties. If you received this transmission in error, please notify us immediately by telephone at 1-800-551-2694.